Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice.
Botulinum toxin
Cervical dystonia
Meta-analysis
Observational study
Journal
Clinical parkinsonism & related disorders
ISSN: 2590-1125
Titre abrégé: Clin Park Relat Disord
Pays: England
ID NLM: 101761473
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
04
2020
revised:
04
06
2020
accepted:
13
06
2020
entrez:
28
7
2021
pubmed:
29
7
2021
medline:
29
7
2021
Statut:
epublish
Résumé
The efficacy and safety of abobotulinumtoxinA in the management of cervical dystonia has been established in randomized, controlled trials that use a selected trial population. In this meta-analysis of observational data, we evaluated the real-life effectiveness of abobotulinumtoxinA as delivered in routine clinical practice. Meta-analysis of patient-level data for adult patients with cervical dystonia treated with abobotulinumtoxinA from three prospective, multicenter, observational studies (NCT01314365, NCT00833196 and NCT01753349). We report data for patients treated with abobotulinumtoxinA over one injection cycle at 181 neurology centers in 35 countries. CD clinical features as assessed by Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total scores ( Findings from this meta-analysis of observational studies confirm the effectiveness of abobotulinumtoxinA in routine practice. Despite inclusion of a broader population sample, the magnitude of improvements observed is consistent with that seen in the pivotal, randomized controlled trials.
Identifiants
pubmed: 34316644
doi: 10.1016/j.prdoa.2020.100063
pii: S2590-1125(20)30031-1
pmc: PMC8298811
doi:
Banques de données
ClinicalTrials.gov
['NCT01314365', 'NCT01753349', 'NCT00833196']
Types de publication
Journal Article
Langues
eng
Pagination
100063Informations de copyright
© 2020 The Authors.
Références
Mov Disord. 2016 Nov;31(11):1649-1657
pubmed: 27653448
J Clin Mov Disord. 2018 Jul 09;5:4
pubmed: 30002865
Neurology. 2016 May 10;86(19):1818-26
pubmed: 27164716
Pain. 1996 Oct;67(2-3):483-91
pubmed: 8951945
J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13-7
pubmed: 9436721
J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1014-9
pubmed: 23687362
Parkinsonism Relat Disord. 2010 Jun;16(5):316-23
pubmed: 20359934
Eur J Neurol. 2011 Jan;18(1):5-18
pubmed: 20482602
Lancet Neurol. 2006 Oct;5(10):864-72
pubmed: 16987733
Eur J Neurol. 2005 Mar;12(3):163-70
pubmed: 15693803
J Neurol. 2001 Dec;248(12):1073-8
pubmed: 12013585
Neurotox Res. 2012 Nov;22(4):265-73
pubmed: 22359151
J Neural Transm (Vienna). 2013 Mar;120(3):487-96
pubmed: 22899277
J Med Econ. 2012;15(3):419-23
pubmed: 22208596
Mov Disord. 2013 Jun 15;28(7):863-73
pubmed: 23649720
Toxins (Basel). 2018 Dec 13;10(12):
pubmed: 30551641
J Neurol. 2015 Oct;262(10):2201-13
pubmed: 25877834
Tremor Other Hyperkinet Mov (N Y). 2013 May 17;3:
pubmed: 23724362
J Neurol Sci. 2015 Feb 15;349(1-2):84-93
pubmed: 25595221
Toxicon. 2018 Jun 1;147:100-106
pubmed: 29407165
Toxins (Basel). 2015 Jun 23;7(6):2321-35
pubmed: 26110508
J Neurol Sci. 2017 May 15;376:84-90
pubmed: 28431634
J Neural Transm (Vienna). 2020 Jun;127(6):935-951
pubmed: 32146504
J Neurol. 2018 Feb;265(2):402-409
pubmed: 29270685
BMJ Open. 2012 Jun 14;2(3):
pubmed: 22700836
Parkinsonism Relat Disord. 2018 Jul;52:94-97
pubmed: 29530726
Mov Disord. 2005 Jul;20(7):783-91
pubmed: 15736159
J Neurol Sci. 2019 Oct 15;405:116413
pubmed: 31494402
Pain Pract. 2016 Nov;16(8):1073-1082
pubmed: 26910788
Eur J Neurol. 2010 Aug;17 Suppl 2:94-108
pubmed: 20633181
J Neurol. 2019 Dec;266(12):3038-3046
pubmed: 31501975